KALA BIO, Inc. (LON:0JQ2)

Market Cap	8.28M -80.7%
Revenue (ttm)	n/a
Net Income	-26.66M
EPS	-4.33
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	847
Average Volume	22,987
Open	0.3998
Previous Close	0.3902
Day's Range	0.3803 - 0.4000
52-Week Range	0.3800 - 20.5710
Beta	-2.45
RSI	32.64
Earnings Date	Mar 27, 2026

About KALA BIO

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2009
• Employees: 38
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JQ2

Financial Performance

Financial numbers in USD